Fenwick represented TRexBio Inc., a discovery stage company decoding tissue immune biology to create therapeutics for immune-mediated diseases, in its multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Under the terms of the agreement, TRexBio grants Janssen an option to an exclusive license to develop and commercialize therapeutics directed against selected targets that may arise from the collaboration, in exchange for an upfront payment, option fees, milestones and royalties. More information about the collaboration can be obtained from TRexBio’s announcement.

The Fenwick transaction team included corporate partner Effie Toshav; technology transactions partner Key Shin; litigation partner Ryan Johnson and associate Eric Majchrzak; and tax partner Will Skinner.

Login

Don’t have an account yet?

Register